Norelgestromin
- Generic Name
- Norelgestromin
- Brand Names
- Evra, Xulane, Zafemy
- Drug Type
- Small Molecule
- Chemical Formula
- C21H29NO2
- CAS Number
- 53016-31-2
- Unique Ingredient Identifier
- R0TAY3X631
- Background
Norelgestromin is a drug used in contraception. Norelgestromin is the active progestin responsible for the progestational activity that occurs in women after application of ORTHO EVRA patch.
- Indication
Norelgestromin is used for contraception and menopausal hormonal therapy. Norelgestromin may potentially be used in breast cancer treatment due to its inhibitory effect on estrone sulfatase . They convert sulfated steroid precursors to estrogen during pregnancy.
- Associated Conditions
- Polycystic Ovarian Syndrome (PCOS)
- Associated Therapies
- Transdermal contraception therapy
Viatris Reports Q1 2025 Results: Pipeline Progress Despite Financial Challenges
• Viatris reported Q1 2025 revenues of $3.3 billion, down 11% on a reported basis but in line with expectations, while experiencing a $2.9 billion non-cash goodwill impairment charge affecting bottom-line results.
• The company achieved significant pipeline progress with three positive Phase 3 data readouts, including novel meloxicam formulation for acute pain, XULANE LO contraceptive patch, and EFFEXOR for anxiety disorder in Japan.
• Despite financial headwinds, Viatris reaffirmed its 2025 financial outlook and capital allocation priorities, returning over $450 million to shareholders year-to-date through dividends and share repurchases.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath